With patents on reference products that treat multiple sclerosis (MS) set to expire soon in the region, a panel of experts in Latin America recently published a set of recommendations regarding the efficacy, safety, and quality of biosimilars in these countries.
With patents on reference products that treat multiple sclerosis (MS) set to expire soon in the region, a panel of experts in Latin America recently published a set of recommendations regarding the efficacy, safety, and quality of biosimilars in these countries.
As in other regions, the expanding use of biosimilars is due to interest in reducing costs, promoting the sustainability of healthcare systems, and improving patient access.
The Latin American Forum of Experts in Multiple Sclerosis gathered experts from Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Panama, Peru, Uruguay, and Venezuela to discuss good practices and risks associated with the use of biosimilar drugs and to develop a set of recommendations as the market expands.
Each country was assessed on its approval of biosimilar drugs by regulatory agencies, use of biosimilar drugs, pharmacovigilance plans and risk management strategies, and knowledge of the latest different molecules.
The availability of MS drugs varies by country and is thus far limited to biosimilar interferons and glatiramer acetate or glatiramoids and other disease-modifying agents, including natalizumab, alemtuzumab, and ocrelizumab.
Original immunomodulatory drugs used for MS treatment have already lost their patents and newer drugs will lose their patents within the next 10 years.
However, every nation’s approval and regulatory process is different; moreover, not every country has pharmacovigilance programs that includes adverse event reporting in the post-marketing phase.
Biosimilars are in use in Argentina, Colombia, Ecuador, Mexico, and Peru, and are expected to expand to other countries in the region.
Brazil is considered to have one of the more advanced regulations regarding biosimilars, as is Argentina, a major manufacturer in Latin America. Other countries, such as Bolivia, are still developing regulations. Countries such as Chile, Mexico, and Venezuela, where foreign exchange controls are in place, are expected to expand.
The Latin American Forum of Experts in Multiple Sclerosis, an independent forum for reaching consensus about MS issues, recommends that each country:
Reference
Steinberg J, Fragoso YD, Duran Quiroz JC, et al. Practical issues concerning the approval and use of biosimilar drugs for the treatment of multiple sclerosis in Latin America [published online May 24, 2019]. Neurol Ther. doi: 10.1007/s40120-019-0139-y.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.